HGH Production and Export Delays Due to Chain of Custody Problems in China
Significant delays in Human Growth Hormone (HGH) production and export from China were attributed to chain of custody problems with the Active Pharmaceutical Ingredients (APIs) used in manufacturing. This was cited as a real-world example of how supply chain integrity failures affect peptide/hormone availability. No specific dosage or protocol information was discussed.
How GH mobilizes (not burns) visceral fat via receptor-density targeting
Bachmeyer clarifies GH does not directly burn fat, it mobilizes it, and preferentially hits visceral fat because visceral adipocytes carry higher GH-receptor density than subcutaneous fat. Mechanistically GH activates JAK2/STAT5 to raise hormone-sensitive lipase and adipose triglyceride lipase while lowering lipoprotein lipase, a dual switch that turns on fat release and off fat storage. He also stresses Tesamorelin is a GHRH analog (a 'reservation' that tells the pituitary to make GH pulsatilely), not GH replacement, so it wakes the somatotrophs rather than shutting them down like exogenous HGH.
HGH fragment 176-191 / AOD9604 is not superior to full HGH for fat loss
Josh treats HGH fragment 176-191 and AOD9604 as essentially the same molecule, the isolated lipolytic portion of the HGH sequence. Because it is derived from HGH, at best it can only match HGH's fat-loss effect while losing all the other benefits (collagen, recovery, tissue repair); he adds that AOD9604 phase-2 trials had placebo outperform the drug, so he calls it likely ineffective and recommends just running 1-2 IU/day of real GH, even for women over 40.
HGH does not shut down natural production the way testosterone does
Josh explains that injecting GH does raise somatostatin and suppress GH output while dosing, but unlike the testes on TRT, the pituitary does not atrophy. Citing childhood GH-deficiency studies, he says the pituitary resumes responding to GHRH within 18-24 hours of the last GH injection regardless of how long it was used, so natural production restarts in under a day after stopping. This is his key reason exogenous HGH can be run long-term without permanent shutdown.
HGH and insulin resistance is dose-dependent, not a fixed side effect
Josh argues HGH short-term worsens insulin sensitivity because it signals the liver to dump glucose and release fatty acids (part of IGF-1 conversion), but long-term at therapeutic 2-4 IU/day it reduces visceral fat and builds muscle (the body's biggest glucose sink), improving metabolic health. He blames the 'GH causes insulin resistance' reputation on bodybuilders using 10-20+ IU/day, which is exactly why they must add exogenous insulin, and calls the concern largely a myth at therapeutic doses with good diet, sleep and optimized testosterone.
Managing GH-driven water retention on Tesamorelin via sodium cycling and DIM
Bachmeyer explains Tesamorelin water retention as real kidney physiology: GH upregulates aquaporin-2 channels and activates the renin-angiotensin-aldosterone system, driving sodium and water reabsorption, and drinking more water worsens it via ADH. His protocol is to deplete sodium below 500 mg/day for 3 days (maintaining ~5 g potassium to avoid dangerous hypokalemia), then reintroduce sodium at ~3 g to reset the osmotic set point, plus berberine and MOTS-c for insulin/SGLT2-driven retention and DIM 300 mg nightly to blunt estrogen-driven aquaporin-2 expression.
HGH injection timing: night for fat loss, carbs/insulin convert GH into IGF-1
Josh describes GH as a paradox: HGH drives lipolysis only when insulin is low, so pre-bed fasted dosing maximizes overnight fat burning, then eating carbs in the morning raises insulin and triggers conversion of circulating GH into IGF-1 for repair and muscle building. Taking GH post-workout with a meal within 30-60 minutes shifts the benefit toward the anabolic/IGF-1 side; for targeted anabolism he prefers keeping GH at night and adding IGF-1 DES pre-workout rather than IGF-1 LR3.
More GH does not linearly raise IGF-1 without calories, insulin, estrogen and training
Explaining a case where raising HGH from 2.4 to 4 IU did not raise IGF-1 (186 to 265 then plateauing at 250), Josh says the GH-to-IGF-1 conversion in the liver depends on caloric intake, healthy estradiol (~40-60 on gear), and hard training intensity more than on GH dose. Crashing E2 with an aromatase inhibitor or under-eating blocks the conversion, so extra GH is wasted. This mirrors the 'IGF-1 caps around 570 ng/mL regardless of GH dose' point attributed to Todd Lee.
Opposing view: secretagogues are inferior to direct HGH except for respecting biology
Josh (Anvil/Apex) takes the opposite stance to Bachmeyer, calling HGH the 'king of peptides' and his ideal protocol 2-4 IU/day at night fasted plus ~250 mg/week testosterone. He argues secretagogues like Tesamorelin and CJC are limited by the pituitary's ceiling and by somatostatin feedback, whereas injecting GH bypasses the pituitary and lets the liver make unlimited IGF-1. Since price is comparable and (he claims) therapeutic HGH doesn't shut down natural production, he sees no upside to secretagogues except preserving natural rhythm, especially after age 50-60 when the pituitary stops responding to GHRH.
Triple secretagogue stack as the pro-longevity alternative to injecting HGH
Rather than exogenous HGH, Bachmeyer stacks Tesamorelin (GHRH analog, ~76% GH increase, visceral-fat targeting), CJC-1295 no-DAC (short half-life for physiological pulsing), and Ipamorelin (ghrelin mimetic that inhibits the somatostatin 'off switch'), claiming the three receptors act multiplicatively to mimic a 20-year-old's nighttime GH pulse while biology still controls release. He stresses dosing once nightly on an empty stomach, 5 days on / 2 off, 12 weeks on / 4 weeks off, warning that continuous use desensitizes pituitary GPCRs (receptor internalization) and 'burns out' the pituitary within ~16 weeks.
Bachmeyer: 'GH causes cancer' is a myth; low GH raises cancer risk
Bachmeyer calls the GH-causes-cancer claim false, reasoning that growth and cancer are not the same, GH has a ~20-minute half-life and does not bind cancer-cell receptors (IGF-1 does), and restoring GH only to youthful physiological levels carries no more risk than a healthy 25-year-old. He claims GH-replacement patients have lower cancer risk than untreated GH-deficient patients (cites a ~34% risk reduction) because adequate GH improves immune surveillance.
Exogenous HGH suppresses your own GH production and adds new side effects
Bachmeyer argues injecting HGH triggers negative feedback: the hypothalamus cuts GHRH, the pituitary becomes less responsive, and somatostatin rises, claiming exogenous HGH suppresses endogenous GH secretion by ~89% in 4 weeks and that recovery of natural pulsatility takes 3-6 months. He says it also causes insulin resistance, carpal tunnel (~34% of long-term users), and gynecomastia, so he only endorses exogenous HGH for a true pituitary problem, not for optimization.
Low growth hormone as the systemic driver of aging and disease
Dr. Trevor Bachmeyer frames GH as the master key to every repair system, arguing low GH is not cosmetic but a disease predictor that degrades fat oxidation, muscle protein synthesis (via IGF-1/mTOR), bone density (osteoblasts), cardiac contractility, thymic/T-cell immune function, and BDNF-driven neuroplasticity. He cites (uncorroborated) figures such as 3.5x impaired lipolysis and 68% reduced fat oxidation in GH-deficient people, and a claimed cohort where the lowest IGF-1 tertile had ~3x cardiovascular mortality and 3.5x cancer incidence.
Optimal Stack Recommendation: IGF-1 DES + HGH as the Preferred Combined Protocol
The speaker's concluding recommendation is to combine IGF-1 DES with HGH as the optimal stacking strategy, allowing users to benefit from both exogenous IGF-1 activity (via DES) and the full systemic benefits of HGH (recovery, sleep, fat loss, endogenous IGF-1 production). This combination is presented as superior to using IGF-1 LR3 with HGH. The recommendation is based on the speaker's applied pharmacokinetic reasoning and coaching experience.
IGF-1 DES Recommended as the Preferred IGF-1 Variant When Stacking With HGH
The speaker recommends IGF-1 DES (des(1-3)IGF-1) as the appropriate IGF-1 variant to use alongside HGH, specifically because its short half-life prevents receptor desensitization. This is presented as the correct stacking strategy when additional IGF-1 activity beyond endogenous production is desired. The recommendation is based on pharmacokinetic reasoning rather than cited clinical data.
Contraindication: Stacking IGF-1 LR3 With HGH Is Discouraged
The speaker explicitly advises against stacking IGF-1 LR3 with HGH, arguing that the combination is counterproductive because IGF-1 LR3 causes receptor desensitization while HGH already maximizes endogenous IGF-1 production. The core argument is that IGF-1 LR3 adds receptor downregulation risk without meaningful additive benefit when HGH is already in use. This is presented as a practical clinical/coaching recommendation.
HGH Provides Benefits Beyond IGF-1 Production: Recovery, Sleep Quality, and Fat Loss
The speaker highlights that exogenous HGH offers systemic benefits independent of its IGF-1-stimulating effects, specifically citing improved recovery, enhanced sleep quality, and fat loss. These pleiotropic effects are used to further justify choosing HGH over direct IGF-1 LR3 injection. No dosage or duration is specified in relation to these benefits.
Three Co-Factors Required to Maximize HGH-Driven IGF-1 Production
The speaker identifies three conditions necessary to optimize hepatic IGF-1 output in response to exogenous HGH: appropriate estrogen (E2) levels, sufficient caloric intake, and an adequate training stimulus. These are framed as modulators of the GH-IGF-1 axis rather than optional considerations. No specific E2 target range or caloric threshold is provided.
Exogenous HGH Drives Hepatic IGF-1 Production Without an Apparent Upper Ceiling
The speaker asserts that the liver will continue to produce IGF-1 in response to exogenous HGH without a fixed upper limit, provided that estrogen (E2) levels are adequate, caloric intake is sufficient, and a proper training stimulus is present. This is presented as a rationale for preferring HGH over direct IGF-1 supplementation. The claim implies a dose-dependent hepatic IGF-1 response to HGH.
HGH Does Not Cause Desensitization of Hepatic Growth Hormone Receptors
The speaker claims that injecting exogenous growth hormone does not cause desensitization of growth hormone receptors in the liver, in contrast to IGF-1 LR3's effect on IGF-1 receptors. This distinction is used to argue in favor of relying on HGH to drive endogenous IGF-1 production rather than injecting IGF-1 LR3 directly. No citation or study is referenced to support this claim.
HGH (Exogenous) Causes Pituitary Damage — Not Recommended
Dr. Bachmeyer strongly advises against exogenous HGH for 99.9% of people, stating it is 'riddled with side effects' and 'causes catastrophic problems with your pituitary.' He distinguishes HGH from GH analogs (CJC-1295, Tesamorelin, Ipamorelin), recommending the analogs instead unless HGH is medically necessary.